Eli Lilly & Co. (LLY) announced results from its Phase 3 EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease Monday afternoon. The results showed that patients with mild Alzheimer's disease taking solanezumab demonstrated a slowing of cognitive decline compared with placebo.
Eli Lilly & Co. climbed steadily following the release of the study results and finished up by 2.55 at $50.78 on strong volume. The stock has been rising for the past week and surged to a new high for the year.
by RTT Staff Writer
For comments and feedback: email@example.com